• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CareDx Inc. (Amendment)

    2/13/24 5:00:59 PM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email
    SC 13G/A 1 tv0531-caredxinc.htm SCHEDULE 13G/A caredxinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 6)*

    Name of issuer:  CareDx Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  14167L103

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  14167L103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    23,749

    7.  SOLE DISPOSITIVE POWER

    4,075,831

    8.  SHARED DISPOSITIVE POWER

    43,851

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,119,682

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.62%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    CareDx Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    8000 Marina Boulevard
    Brisbane, CA 94005

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    14167L103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $CDNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    1/6/2026$26.00Buy → Hold
    Craig Hallum
    8/26/2025Mkt Perform
    William Blair
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    More analyst ratings

    $CDNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

    CareDx, Inc. (NASDAQ:CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx’s Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a dial-in number and unique PIN will be provided. About CareDx CareDx is a leading pr

    7/16/26 8:35:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination

    Coverage for Surveillance Testing Affirmed for Early Detection of Allograft Rejection in Kidney, Heart, and Lung CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization of the Medicare Local Coverage Determination (LCD) process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across CareDx’s transplant surveillance offerings in kidney, heart, and lung. Kidney: The policy affirms coverage of AlloSure® Kidney for surveillance testing for up to six tests in the first-year post-transplant and for up to four tests per year in years two

    7/16/26 8:30:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology

    NavDx® is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers Expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell therapy CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202607015393

    7/1/26 4:05:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Hanna John Walter Jr exercised 118,000 shares at a strike of $8.20 and sold $4,458,637 worth of shares (118,000 units at $37.79) as part of a pre-agreed trading plan (SEC Form 4)

    4 - CareDx, Inc. (0001217234) (Issuer)

    7/17/26 4:23:30 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Director Valantine Hannah exercised 28,779 shares at a strike of $14.76 and sold $1,040,243 worth of shares (28,779 units at $36.15) as part of a pre-agreed trading plan (SEC Form 4)

    4 - CareDx, Inc. (0001217234) (Issuer)

    7/17/26 4:22:50 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Director Goldberg Michael was granted 1,746 shares, increasing direct ownership by 2% to 106,438 units (SEC Form 4)

    4 - CareDx, Inc. (0001217234) (Issuer)

    7/7/26 5:53:29 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CareDx downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded CareDx from Buy to Hold and set a new price target of $26.00

    1/6/26 9:07:34 AM ET
    $CDNA
    Medical Specialities
    Health Care

    William Blair initiated coverage on CareDx

    William Blair initiated coverage of CareDx with a rating of Mkt Perform

    8/26/25 8:17:26 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously

    1/15/25 7:29:19 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    SEC Filings

    View All

    CareDx Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CareDx, Inc. (0001217234) (Filer)

    7/7/26 5:12:41 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - CareDx, Inc. (0001217234) (Filer)

    6/15/26 4:15:45 PM ET
    $CDNA
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by CareDx Inc.

    DEFA14A - CareDx, Inc. (0001217234) (Filer)

    6/5/26 4:27:01 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/14/24 5:13:57 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/8/24 2:34:10 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/5/24 6:07:26 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Leadership Updates

    Live Leadership Updates

    View All

    CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

    Kennedy brings seven years of public company CFO experience CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company's Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company's finance organization effective February 26, 2026. Kennedy brings to CareDx over 20 years of experience and executive leadership in healthcare including global diagnostics, biopharma services, and contrac

    2/24/26 5:15:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

    Renowned Transplant Clinician to Lead CareDx Global Medical Affairs CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, effective October 1, 2025. Dr. Teuteberg brings more than two decades of experience in clinical transplantation, including senior leadership roles at Stanford University and the University of Pittsburgh Medical Center. He is board certified in Heart Failure/Cardiac Transplantation

    10/27/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors

    CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the appointment of Suresh Gunasekaran to its Board of Directors. Suresh currently serves as President and Chief Executive Officer at UCSF Health, an internationally renowned health system for providing highly specialized and innovative care, including solid organ and bone marrow transplantation. Suresh has more than 20 years of executive leadership experience in healthcare administration and information technology, with a proven track record of driving operational

    10/22/25 4:01:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $CDNA
    Financials

    Live finance-specific insights

    View All

    CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

    CareDx, Inc. (NASDAQ:CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx’s Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a dial-in number and unique PIN will be provided. About CareDx CareDx is a leading pr

    7/16/26 8:35:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx to Report First Quarter 2026 Financial Results on April 28, 2026

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, April 28, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone,

    4/14/26 4:01:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference ca

    2/10/26 4:01:00 PM ET
    $CDNA
    Medical Specialities
    Health Care